These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 37155018)
1. Orexin pathway in Parkinson's disease: a review. Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Zaafar D; Batiha GE Mol Biol Rep; 2023 Jul; 50(7):6107-6120. PubMed ID: 37155018 [TBL] [Abstract][Full Text] [Related]
2. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Liu C; Xue Y; Liu MF; Wang Y; Chen L Neurochem Int; 2020 Sep; 138():104754. PubMed ID: 32422324 [TBL] [Abstract][Full Text] [Related]
3. Exploring the Role of Orexinergic Neurons in Parkinson's Disease. Kumar S; Behl T; Sehgal A; Singh S; Sharma N; Bhatia S; Al-Harassi A; Abdel-Daim MM; Bungau S Neurotox Res; 2021 Dec; 39(6):2141-2153. PubMed ID: 34495449 [TBL] [Abstract][Full Text] [Related]
5. Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review. Raheel K; See QR; Munday V; Fakhroo B; Ivanenko O; Salvatelli ML; Mutti C; Goadsby PJ; Delogu A; Naismith SL; Holland P; Parrino L; Chaudhuri KR; Rosenzweig I Curr Neurol Neurosci Rep; 2024 Sep; 24(9):389-412. PubMed ID: 39031323 [TBL] [Abstract][Full Text] [Related]
6. Orexinergic neurons are involved in the chemosensory control of breathing during the dark phase in a Parkinson's disease model. Oliveira LM; Falquetto B; Moreira TS; Takakura AC Exp Neurol; 2018 Nov; 309():107-118. PubMed ID: 30110606 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease. Stanojlovic M; Pallais JP; Kotz CM Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466831 [TBL] [Abstract][Full Text] [Related]
8. Hypocretin (orexin) cell loss in Parkinson's disease. Thannickal TC; Lai YY; Siegel JM Brain; 2007 Jun; 130(Pt 6):1586-95. PubMed ID: 17491094 [TBL] [Abstract][Full Text] [Related]
9. Several neuropeptides involved in parkinsonian neuroprotection modulate the firing properties of nigral dopaminergic neurons. Chen L; Liu C; Xue Y; Chen XY Neuropeptides; 2023 Jun; 99():102337. PubMed ID: 37087783 [TBL] [Abstract][Full Text] [Related]
10. Orexin-B exerts excitatory effects on nigral dopaminergic neurons and alleviates motor disorders in MPTP parkinsonian mice. Bian K; Liu C; Wang Y; Xue Y; Chen L Neurosci Lett; 2021 Nov; 765():136291. PubMed ID: 34666119 [TBL] [Abstract][Full Text] [Related]
11. Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity. Stanojlovic M; Pallais Yllescas JP; Vijayakumar A; Kotz C Mol Neurobiol; 2019 Dec; 56(12):8435-8450. PubMed ID: 31250383 [TBL] [Abstract][Full Text] [Related]
12. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons. Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288 [TBL] [Abstract][Full Text] [Related]
13. Glymphatic System Dysfunction and Sleep Disturbance May Contribute to the Pathogenesis and Progression of Parkinson's Disease. Scott-Massey A; Boag MK; Magnier A; Bispo DPCF; Khoo TK; Pountney DL Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361716 [TBL] [Abstract][Full Text] [Related]
14. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients. Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104 [TBL] [Abstract][Full Text] [Related]
15. BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy. Ali NH; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; AlAseeri AA; Alruwaili M; Saad HM; Batiha GE J Cell Mol Med; 2024 May; 28(10):e18368. PubMed ID: 38752280 [TBL] [Abstract][Full Text] [Related]
16. Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit. Alharbi B; Al-Kuraishy HM; Al-Gareeb AI; Elekhnawy E; Alharbi H; Alexiou A; Papadakis M; Batiha GE Eur J Med Res; 2024 Mar; 29(1):205. PubMed ID: 38539252 [TBL] [Abstract][Full Text] [Related]
17. The Mechanism of SNHG8/Microrna-421-3p/Sorting Nexin 8 Axis on Dopaminergic Neurons in Substantia Nigra in a Mouse Model of Parkinson's Disease. Zhou S; Zhou X; Jiang Z; Ma J; Li Y; Qian Z; Li H Neurochem Res; 2023 Mar; 48(3):942-955. PubMed ID: 36401052 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease. Stanojlovic M; Pallais JP; Lee MK; Kotz CM Mol Brain; 2019 Oct; 12(1):87. PubMed ID: 31666100 [TBL] [Abstract][Full Text] [Related]